Search
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057,L4274,L4278] Additionally, Galafold was also granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing … [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.
Synonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineInternational brands: Nolvadex-DDesflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285] … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].
Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedThe average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia.
Products: LONQUEX SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6MLTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigationalCTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [A243759] The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawnChymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin. … [A274308] Donidalorsen is a ligand-conjugated antisense oligonucleotide that reduces plasma prekallikrein production, thereby reducing bradykinin production and preventing the initiation of attacks.
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SP, -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL)Categories: Drugs Used in Hereditary AngioedemaSalicylamide
go.drugbank.com/drugs/DB08797ApprovedSalicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. … Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
Synonyms: o-hydroxybenzamideMixtures: CON-Z-LIN TABLETCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[L40739] Re-infusion of these modified T-cells leads to the targeted elimination of malignant plasma cells, on which BCMA is highly expressed. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development